Introduction {#Sec1}
============

Alzheimer's disease (AD) is the most common progressive neurodegenerative disease. The annual incidence of AD is currently estimated at 4.6 million cases, and as the general population ages, the worldwide prevalence is expected to increase to more than 80 million cases by the year 2040 (Ferri et al. [@CR13]). Currently, the treatment options for AD only ameliorate the symptoms and do not inhibit the natural progression of AD. Strong evidence has shown that amyloid beta (Aβ) plaques and tau-associated neurofibrillary tangles (NFTs) "clog" the brain and prevent neuronal communication in patients with AD, causing further brain dysfunction (Braak and Braak [@CR6], [@CR7]). Many studies have found that both Aβ and tau drive the pathogenesis of AD by modulating glycogen synthase kinase 3 (GSK3) activity (Querfurth and LaFerla [@CR42]). Accumulating evidence has demonstrated that GSK3β plays a role in tau hyperphosphorylation and the associated memory impairment in AD (Dolan and Johnson [@CR12]). In addition, the oxidative stress, inflammation, and neuroinflammation associated with AD are also mediated by GSK3β activation (Zhang et al. [@CR54]; D'Angelo et al. [@CR11]). Evidence also shows that GSK-3β is a potential link between diabetes mellitus (DM) and AD (Zhang et al. [@CR55]), and DM might accelerate the progression of AD (Guo et al. [@CR17]). According to the announcement by Jackson laboratory at February 2014, male 3xTg-AD mice may not exhibit the phenotypic traits originally described by donating investigator. Therefore, hyperglycemia was applied to accelerate the phenotypes of 3xTg-AD mice at 6 months old in the study.

Extensive evidence has shown that the endocannabinoid system is an important regulator of synaptic function (Hill et al. [@CR20]; Campolongo et al. [@CR8]). Animal studies have also demonstrated that the endocannabinoid system modulates recognition memory by selectively affecting encoding within the hippocampus (Barna et al. [@CR4]). *N*-arachidonoylphenolamine (AM404), a paracetamol lipid metabolite, acts as a modulator of the endocannabinoid system and is endowed with pleiotropic activities including activating transient receptor potential vanilloid receptor 1 (TRPV1), inhibiting fatty acid amide hydrolase (FAAH)-mediated hydrolysis of *N*-arachidonoyl ethanolamide (anandamide; AEA), and inhibiting the synthesis of cyclooxygenase (COX)-1, COX-2, and prostaglandin (Hogestatt et al. [@CR21]). Several studies have also shown that AM404 has a role in the extinction of fear memories in rats (Bitencourt et al. [@CR5]), produces anxiolytic and antidepressant-like effects in rats and mice (Patel and Hillard [@CR39]; Adamczyk et al. [@CR2]), and is neuroprotective in ischemic gerbils (Zani et al. [@CR53]) and rats with Parkinson's disease (Garcia-Arencibia et al. [@CR15]). We previously utilized a virtual screening system and a series of biochemical assays to show that the concentration of AM404 necessary to half-maximally inhibit GSK-3β kinase activity (IC50) is 5.353 μM (Lin et al. [@CR27]). Using cell-based assays, we also showed that AM404 increased Ser 9-phospho-GSK3β (pS9-GSK3β) expression, reduced tau phosphorylation, enhanced heat shock 27 kDa protein 1 (HSPB1) and glucose-regulated protein 78 kDa (GRP78) expression, increased tau solubility, and promoted neurite outgrowth (Lin et al. [@CR27]). However, previous studies suggests that intraperitoneal injection of AM404 (10 mg/kg) not only impaired long-term potentiation through the hippocampal Schaffer collateral-CA1 projection (Abush and Akirav [@CR1]) but also potentiated restraint-induced corticosterone release (Patel et al. [@CR40]). Evidence from clinical trial further points out that the effects of GSK3β inhibitors were correlated to the dose and duration of treatment in AD (Lovestone et al. [@CR28]). Based on these reports, the current study was designed to examine whether AM404 at low dose exerts neuroprotective effects and improves cognitive deficits and pathological features of AD in primary murine hippocampal neuron cultures and hyperglycemic 3×Tg-AD mice.

In this study, AM404 at 0.5 μM exerted neuroprotective effects on primary murine hippocampal neuron cultures by inhibiting tau toxicity. In addition, chronic administration of AM404 at low dose (0.25 mg/kg; i.p.) improved spatial cognition and attenuated pathological features, which might be in part by the Akt/GSK3β pathway in hyperglycemic 3×Tg-AD mice. Therefore, we suggest that chronic systemic administration of AM404 at low dose could be a potential therapeutic for AD, which might be through Akt/GSK3β pathway, not dependent by a direct GSK3β inhibitor, or receptor of CB1 and TRVP1.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Pregnant female C57BL/6J and male 3×Tg-AD mice were purchased from the National Breeding Centre for Laboratory Animals (Taipei, Taiwan) and Jackson Laboratory (004807; Bar Harbor, ME, USA), respectively. Mice were housed in individual ventilated cages at 20--25 °C, with free access to food and water and a 12/12-h light/dark cycle (7 AM to 7 PM). Mice were deeply anesthetized with Avertin (0.4 g/kg body weight, Sigma, St. Louis, MO, USA) and then sacrificed to conduct pathological analyses; all efforts were made to minimize suffering.

Experimental timeline for the 3×Tg-AD mice {#Sec4}
------------------------------------------

Male 3×Tg-AD mice obtained from Jackson Laboratory (004807; Bar Harbor, ME, USA) only exhibit a mild phenotype at 6 months of age. Therefore, hyperglycemia was induced using streptozotocin (STZ) to accelerate disease progression in the 6-month-old male 3×Tg-AD mice. Following a 6-h fasting period, STZ (100 mg/kg in 0.1 ml sodium citrate buffer, pH 4.5, Sigma, St. Louis, MO, USA) was intraperitoneally (i.p.) injected into the 3×Tg-AD mice on days 1, 2, 8, and 9 to induce hyperglycemia (*n* = 30). An equivalent volume of sodium citrate buffer was i.p. injected into a subgroup of mice (*n* = 30) to create a normoglycemic group (NBG). Blood samples were obtained from all mice by tail prick, and glucose levels were measured using a commercial glucometer (Accu-Check Active, Roche, Mannheim, Germany). The STZ-treated mice that had developed hyperglycemia by day 14 (defined as a blood glucose concentration ≥ 200 mg/dl) were included in the study as the hyperglycemic group (HBG). The dose of AM404 (0.25 mg/kg/day; Sigma) was determined based on the results obtained from primary hippocampal neuronal cultures (Supporting Information [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}) and was slightly modified according to the dose used in a previous study (Miller et al. [@CR31]). AM404 was i.p. injected into the mice starting on day 14 and lasting for 4 weeks. The mice were divided into four groups: (i) NBG/vehicle (*n* = 15), (ii) NBG/AM404 (*n* = 15), (iii) HBG/vehicle (*n* = 8), and (iv) HBG/AM404 (*n* = 9). Body weights and blood glucose levels were monitored weekly during the treatment (Supporting Information [S3](#MOESM1){ref-type="media"}). The Morris water maze (MWM) was conducted on days 34--42 to evaluate the spatial learning abilities and memory capacities of the mice. The mice were sacrificed on day 43 for pathological and molecular characterization (Supporting Information [S3](#MOESM1){ref-type="media"}).

MWM {#Sec5}
---

The MWM was performed based on previously described methods to evaluate the spatial learning abilities and memory capacities of the treated mice (Huang et al. [@CR23]). Briefly, a circular pool (height 47 cm, diameter 100 cm) was filled with opaque water (24 ± 1 °C), and a hidden square platform (10 cm^2^) was submerged 1 cm below the surface of the water in the center of the northeast quadrant, which served as the target quadrant. A video camera was attached to the ceiling to record the behavior of the mice in the pool, which was analyzed using EthoVision software (Noldus, Wageningen, Netherlands). During the four training days, each mouse underwent four trials per day. Each mouse was released into the water maze from a random starting point in each trial. The time that each mouse spent locating the hidden platform (i.e., the escape latency) was calculated, and a curve was generated to represent the data collected over the four training days, which represented the learning profiles of the mice. Twenty-four hours after the final training trial, three testing trials were conducted to determine the time required to find the hidden platform as a measure of spatial learning acquisition. A probe trial was conducted 48 h after the end of the testing trials to evaluate long-term spatial memory. Each mouse was allowed to swim freely for 60 s, and the time the mouse spent in the target quadrant (where the platform was removed) was measured to represent the degree of memory consolidation after learning.

Western blot analysis {#Sec6}
---------------------

Mouse hippocampal tissues (*n* = 3--5 per group) were homogenized, and the concentrations of the isolated proteins were determined using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA). The homogenates (25 μg of protein each) were subsequently separated using SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. Blots were then blocked in 5% (*w*/*v*) skim milk to reduce nonspecific binding and probed with the following primary antibodies: pS473Akt (1:1000; Cell Signaling Technology, Danvers, MA, USA); Akt (for Akt1--3; 1:1000; Cell Signaling Technology, Danvers, MA, USA); pS9-GSK3β (1:1000; Cell Signaling Technology, Danvers, MA, USA); pY216-GSK3β (1:1000; Millipore, Temecula, MA, USA); GSK3β (1:1000; Cell Signaling Technology, Danvers, MA, USA); HT7 (1:500; Thermo Fisher Scientific, Rockford, IL, USA); tau phosphorylated at S396 (1:1000; Invitrogen, Rockford, USA), S202 (1:1000; AnaSpec, San Jose, CA, USA), and T231 (1:1000; Invitrogen, Rockford, IL, USA); beta-secretase 1 (BACE1; 1:1000; Cell Signaling Technology, Danvers, MA, USA); insulin-degrading enzyme (IDE; 1:1000; Abcam, Cambridge, UK); neprilysin (NEP; 1:1000; Santa Cruz Biotechnology, Dallas, Texas, USA); and β-actin (1:2000; Millipore, Temecula, CA, USA). These incubations were followed by incubations with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (1:10,000; Amersham Pharmacia Biotech, Piscataway, NJ, USA). The protein bands were scanned using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The immunoreactive bands were quantified using an LAS-4000 chemiluminescence detection system (Fujifilm; Tokyo, Japan).

Immunohistochemical staining {#Sec7}
----------------------------

Immunohistochemical (IHC) staining was conducted as previously described (Huang et al. [@CR22]). Briefly, after the MWM, the mice (*n* = 3--5 per group) were deeply anesthetized with Avertin (0.4 g/kg body weight) and then perfused through the heart with normal saline followed by ice-cold 4% PFA in 0.1 mol/L phosphate-buffered saline (PBS, pH 7.0). The brains of the mice were then removed and post-fixed in the same solution at 4 °C for 24 h. Then, the brains were dehydrated in a graded series of sucrose solutions until they were fully permeated. Thereafter, 30-μm-thick frozen sections were cut in the coronal plane using a cryostat microtome (CMS3050S; Leica Microsystems; Nussloch, Germany). The free-floating sections were incubated with primary antibodies against Aβ~40~ (1:2000; Invitrogen, Rockford, IL, USA), Aβ~42~ (1:500; Invitrogen, Rockford, IL, USA), tyrosine hydroxylase (TH; for noradrenergic neurons; 1:1000; Millipore, Temecula, CA, USA), 5-hydroxytryptamine (5HT; for serotonergic neurons; 1:200; Millipore, Temecula, CA, USA), choline acetyltransferase (ChAT; for cholinergic neurons; 1:1000; Millipore, Temecula, CA, USA), Iba-1 (for microglia; 1:1000; Wako, Osaka, Japan), and glial fibrillary acidic protein (GFAP; for astrocytes; 1:1000; Millipore, Temecula, CA, USA) overnight at room temperature. On the second day, the sections were washed in PBS and incubated with the appropriate biotinylated secondary antibodies (1:200 dilution; Vector Laboratories, CA, USA) followed by incubation with an avidin--biotin--peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories, CA, USA) for 1 h at room temperature. Immunoreactivity was visualized with a diaminobenzidine (DAB) kit (Vector Laboratories, CA, USA). After terminating the reaction by the addition of PBS, the sections were mounted, dehydrated, and coverslipped. For each analysis, three slices of each mouse hippocampus and brainstem were stained, and three to five mice were used for each group. For each slice, the Aβ~40~ and Aβ~42~ staining in the CA1 subregion of the hippocampus, astrocyte (GFAP) and microglia (ionized calcium-binding adapter molecule 1, Iba1) staining in the whole hippocampus, and serotonergic (5-HT) and noradrenergic neuron (TH) staining in the raphe nucleus and locus coeruleus (LC) region of the brainstem were observed using a light microscope (Leica; Wetzlar, Germany). All images were analyzed using digital image analysis software Image Pro Plus (IPP; Media Cybernetics, MD). A positive-staining cell in the specific area, such as hypertrophic astrocytes; activated microglia, Aβ~40~, and Aβ~42~ in hippocampus; serotonergic neurons in Raphe nucleus; and noradrenergic neurons in LC region was selected as a standard signal, and the numbers of positive cells were then counted by the IPP software system. Pixel counts were derived from the average of three adjacent sections per animal.

Enzyme-linked immunosorbent assay analysis {#Sec8}
------------------------------------------

Prior to sacrifice, blood samples were collected from the mice via a facial vein using a lancet (*n* = 3--5 per group). The blood samples were centrifuged at 2000×*g* for 20 min at 4 °C. Thereafter, the supernatants were collected as serum samples and stored at − 80 °C until further examination. The levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in the serum samples were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, MN, USA).

Data analysis {#Sec9}
-------------

All values are expressed as means ± standard errors of the means (SEM). The statistical analyses were performed using SPSS 16.0 software. The interactions and effects between the factors in the MWM were analyzed using a two-way analysis of variance (ANOVA, general linear model). The other data were analyzed using a one-way ANOVA followed by a least significant difference (LSD) post hoc test. Comparisons between two groups were performed using independent Student's *t* tests or nonparametric tests (Kruskal--Wallis test). For all tests, *P* \< 0.05 was considered significant.

Results {#Sec10}
=======

AM404 attenuates spatial learning and memory impairments in hyperglycemic 3×Tg-AD mice {#Sec11}
--------------------------------------------------------------------------------------

The neuroprotective effect of AM404 on tau hyperphosphorylation in primary murine hippocampal neurons and *Drosophila* model has been confirmed (Supporting Information [S1](#MOESM1){ref-type="media"}--[S3](#MOESM1){ref-type="media"}). Therefore, AM404 was further applied to hyperglycemic 3×Tg-AD mice to validate its in vivo function. AM404 had no effects on body weights or blood glucose levels in these mice (Supporting Information [S4](#MOESM1){ref-type="media"}). The MWM was conducted on days 34--42 to evaluate the spatial learning abilities and memory capacities of the mice. Based on the results of the two-way ANOVA, no significant interactions were observed between hyperglycemia and AM404 with regard to swimming velocity, spatial learning ability, or spatial memory retrieval in the 3×Tg-AD mice (data not shown). In addition, no differences in swimming velocity were observed among the four groups of mice (Fig. [1](#Fig1){ref-type="fig"}a). During the four training days, the NBG groups presented normal learning abilities following the administration of vehicle (*F*(3,19) = 4.799, *P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}b) or AM404 (*F*(3,24) = 3.801, *P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}b). The vehicle-treated HBG group showed significantly poorer spatial learning abilities from training days 1 to 4 (*F*(3,24) = 2.201, *P* \> 0.05; Fig. [1](#Fig1){ref-type="fig"}b). The AM404 treatment significantly reduced the spatial learning impairments in this group (*F*(3,15) = 3.782, *P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}b). In addition, the STZ injections impaired the acquisition of spatial learning during the test trial (*P* \< 0.01, Fig. [1](#Fig1){ref-type="fig"}c) and long-term memory retrieval during the probe trial (*P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}d) in the HBG group, whereas the AM404 treatment ameliorated the impairments in spatial learning acquisition (*P* \< 0.01; Fig. [1](#Fig1){ref-type="fig"}c) and memory consolidation (*P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1Effects of AM404 on the learning and memory capacities of hyperglycemic 3×Tg-AD mice. **a** Swimming velocity was measured on the testing day. No differences were identified among the four groups of mice. **b** The learning profiles of the four groups of mice during the four training days. AM404 improved the learning ability in the HBG groups. **c** Latency in the identification of the platform during the testing trials. The hyperglycemic mice spent more time finding the platform than the control mice, and AM404 treatment ameliorated this impairment. **d** The results of the long-term memory retrieval testing. Hyperglycemia enhanced the impairment of long-term memory retrieval, and AM404 attenuated this deficit. Data are presented as the means ± SEM of each group. *n* = 15 (NBG with vehicle group), 15 (NBG with AM404 group), 8 (HBG with vehicle group), and 9 (HBG with AM404 group). \**P* \< 0.05; \*\**P* \< 0.01

AM404 upregulates Akt and reduces tau phosphorylation in hyperglycemic 3×Tg-AD mice {#Sec12}
-----------------------------------------------------------------------------------

Mice were sacrificed after the MWM task, and their hippocampi were isolated for western blot analysis (Fig. [2](#Fig2){ref-type="fig"}a). The ratios of both pS473Akt/Akt and pS9-GSK3β/GSK3β were decreased in the HBG group (*P* \< 0.05; Fig. [2](#Fig2){ref-type="fig"}b, c). The levels of the tau protein phosphorylated at Ser202, Ser396, and Thr231 were also increased in this group (*P* \< 0.05--0.01; Fig. [2](#Fig2){ref-type="fig"}d--f). All of the indices related to the tau toxicity induced by hyperglycemia were attenuated by the AM404 treatment (*P* \< 0.05--0.01; Fig. [2](#Fig2){ref-type="fig"}b--f) (*n* = 3--5).Fig. 2Effect of AM404 on tau hyperphosphorylation in hyperglycemic 3×Tg-AD mice. Representative western blots (**a**) and quantitative densitometry results for the pS473Akt/Akt ratio (**b**), pS9-GSK3β/GSK3β ratio (**c**), and ratio of tau phosphorylated sites Ser202 (**d**), Ser396 (**e**), and Thr231 (**f**) to actin. β-Actin was used as an internal control. The quantitative data are presented as the means ± SEM of each group (*n* = 3--5 per group). Asterisk, compared to NBG with vehicle group; number sign, compared to HBG with vehicle group (\*^,\#^*P* \< 0.05; \*\*^,\ \#\#^*P* \< 0.01)

AM404 attenuates Aβ levels and BACE1 expression in hyperglycemic 3×Tg-AD mice {#Sec13}
-----------------------------------------------------------------------------

Intracellular Aβ deposition in the hippocampus plays an important role in the cognitive dysfunction of AD. Therefore, we examined the intracellular Aβ levels in the hippocampi of 3×Tg-AD mice. Significantly increased Aβ~40~ and Aβ~42~ levels were detected in the HBG group compared with the NBG group (*P* \< 0.05--0.01; Fig. [3](#Fig3){ref-type="fig"}a; Table [1](#Tab1){ref-type="table"}), and the AM404 treatment reduced the Aβ~40~ (*P* \< 0.01) and Aβ~42~ (*P* \< 0.05) levels compared to the vehicle-treated HBG group (Fig. [3](#Fig3){ref-type="fig"}a; Table [1](#Tab1){ref-type="table"}) (*n* = 3--5). Hyperglycemia increased BACE1 expression, which was significantly reduced by AM404 administration (*P* \< 0.05; Fig. [3](#Fig3){ref-type="fig"}b). In addition, hyperglycemia or AM404 had no effects on IDE and NEP expression (Fig. [3](#Fig3){ref-type="fig"}c, d). Therefore, these results indicate that AM404 attenuated Aβ production in the hippocampi of 3×Tg-AD mice under hyperglycemic conditions, which may result from reduced BACE1 expression.Fig. 3Effect of AM404 on the Aβ levels in the hippocampi of hyperglycemic 3×Tg-AD mice. **a** Representative immunohistochemical staining of amyloid deposits in the mouse hippocampal CA1 region using Aβ~40~ and Aβ~42~ antibodies. Scale bar = 100 μm. The arrowheads indicate the positive staining (*n* = 3--4 per group; the quantitative results are shown in Table [1](#Tab1){ref-type="table"}). Representative western blots and quantitative densitometry results for the BACE1 (**b**), IDE (**c**), and NEP (**d**) expression levels. β-Actin was used as an internal control. The quantitative data are presented as the means ± SEM of each group (*n* = 3--5 per group). Asterisk, compared to the NBG with vehicle group; number sign, compared to the HBG with vehicle group (\*^,\ \#^*P* \< 0.05)Table 1Quantitative results of the immunohistochemical stainingNormoglycemia (NBG)Hyperglycemia (HBG)VehicleAM404VehicleAM404Aβ~40~172.17 ± 7.61181.88 ± 4.17212.92 ± 10.49 **↑↑**^a^164.78 ± 9.51 **↓↓**^b^Aβ~42~27.50 ± 1.2029.13 ± 0.6433.00 ± 2.07 **↑**^a^26.91 ± 1.28 **↓**^b^Hypertrophic astrocytes (GFAP)2.50 ± 0.423.33 ± 1.0243.19 ± 3.46 **↑↑↑**^a^15.63 ± 2.05 **↓↓↓**^b^Activated microglia (Iba1)36.08 ± 1.1634.25 ± 2.1962.53 ± 1.16 **↑↑↑**^a^29.43 ± 0.78 **↓↓↓**^b^Serotonergic neurons (5HT)35.67 ± 0.9231.80 ± 2.0419.00 ± 1.34 **↓↓↓**^a^33.00 ± 1.78 **↑↑↑**^b^Noradrenergic neurons (TH)75.60 ± 4.9775.75 ± 3.1245.79 ± 2.66 **↓↓↓**^a^56.89 ± 4.45 **↑**^b^Data are shown as the mean ± SEM^a^Compared with NBG/vehicle^b^Compared with HBG/vehicle↑ Increased (*P* \< 0.05); ↑↑ increased (*P* \< 0.01); ↑↑↑ increased (*P* \< 0.001)↓ Decreased (*P* \< 0.05); ↓↓ decreased (*P* \< 0.01); ↓↓↓ decreased (*P* \< 0.001)

AM404 suppresses inflammation and reduced the neuronal loss in hyperglycemic 3×Tg-AD mice {#Sec14}
-----------------------------------------------------------------------------------------

Neuroinflammation in the mouse hippocampus was substantially increased by hyperglycemia as determined by GFAP (hypertrophic astrocytes, *P* \< 0.001) and Iba1 (activated microglia, *P* \< 0.001) staining (Fig. [4](#Fig4){ref-type="fig"}a; Table [1](#Tab1){ref-type="table"}). AM404 effectively attenuated both astrogliosis and microgliosis (*P* \< 0.001; Fig. [4](#Fig4){ref-type="fig"}a; Table [1](#Tab1){ref-type="table"}). Furthermore, the HBG groups showed elevated serum levels of the inflammatory cytokines IL-6 and TNF-α, which were also ameliorated by the AM404 treatment (*P* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}b, c). In addition, the AM404 treatment significantly reduced the IL-6 and TNF-α levels in the NBG groups (*P* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}b, c). Furthermore, according to the immunohistochemical analyses, AM404 significantly protected serotonergic (*P* \< 0.001) and noradrenergic neurons (*P* \< 0.05) in hyperglycemic 3×Tg-AD mice (Table [1](#Tab1){ref-type="table"}; Supporting Information [S5](#MOESM1){ref-type="media"}). These results revealed that chronic low dose of AM404 has strong anti-inflammatory properties and reduced the loss of serotonergic and noradrenergic neurons in hyperglycemic 3×Tg-AD mice.Fig. 4Effect of AM404 on inflammation in hyperglycemic 3×Tg-AD mice. **a** Representative immunohistochemical staining of astrocytes using an anti-GFAP antibody and microglia using an anti-Iba1 antibody in mouse hippocampal tissue. Scale bar = 100 μm. The arrowheads indicate the positive staining for activated microglia and astrocytes, which are magnified in the insets of each figure (*n* = 3--4 per group; the quantitative results are shown in Table [1](#Tab1){ref-type="table"}). **b** Levels of the inflammatory cytokine IL-6 as determined in mouse serum by ELISA (*n* = 3--5 per group). **c** Levels of the inflammatory cytokine TNFα as determined in mouse serum by ELISA (*n* = 3--5 per group). Asterisk, compared to the NBG with vehicle group; number sign, compared to the HBG with vehicle group (\*^,\ \#^*P* \< 0.05)

Discussion {#Sec15}
==========

Based on the data presented in the current study, administration of AM404 at low dose significantly induced neuroprotection in primary mouse hippocampal neuronal culture incubated with WT/GFX and reduced cognitive deficits associated pathological features, which might be partly through Akt/GSK3β pathway in hyperglycemic 3×Tg-AD mice. Therefore, we propose that chronic low dose of AM404 may be used as an indirect GSK3β inhibitor in AD.

From our in vitro results, WT/GFX application in mouse primary hippocampal neuronal culture reduced the levels of pS9-GSK3β (inactive form) expression and increased tau protein phosphorylation at S396 site. These results were consistent with the previous study (Shi et al. [@CR46]). However, the administration of AM404 at 0.5 μM induced the neuroprotection against the toxicity-induced by WT/GFX in primary hippocampal neuronal culture. In addition, as described in recent investigations (Xiang et al. [@CR51]; Chao et al. [@CR9]), the current study used hyperglycemia to increase spatial learning and memory deficits associated with more severe pathological presentations in 3×Tg-AD mice. Cognitive dysfunction associated with neuropathological hallmarks, such as amyloid deposition, tau protein hyperphosphorylation, and gliosis, was used to highlight several primary concerns during AD and diabetes mellitus (DM) (Halmos and Suba [@CR18]). Previous evidence has also suggested that impaired glucose metabolism in mild cognitive impairment (MCI) is associated with increased progression to AD (Morris et al. [@CR33]). Furthermore, hyperglycemia has been shown to increase the prevalence of AD in APP/PS1 transgenic mice (Wang et al. [@CR49]). Therefore, we confirmed that the induction of hyperglycemia increased the progression of cognitive dysfunction and pathological features in 3×Tg-AD mice. In addition, the chronic systemic administration of AM404 (0.25 mg/kg) improved spatial learning and memory in the hyperglycemic 3×Tg-AD mice. Our previous biochemical assay identified that the concentration of the compound necessary to half-maximally inhibit GSK-3β kinase activity (IC50) is 5.353 μM (Lin et al. [@CR27]), which is much less potent than the known inhibitors, SB216763 (IC50 = 0.018 μM) and SB415286 (IC50 = 0.248 μM). In addition, it has been reported that the dose of AM404 targeting on the TRPV1 and cannabinoid (CB) receptors exceeds 10 μM (in vitro) and 10 mg/kg (in vivo; i.p.) (Pertwee [@CR41]; Saliba et al. [@CR45]). Therefore, the effective doses of AM404 used in this study, 0.5 μM (in vitro) and 0.25 mg/kg (in vivo), might not work as a direct GSK3β inhibitor and independent on TRPV1 and CB1 receptors. In addition to the specific targets CB1 or TRPV1 receptors, the effects of AM404 might be also dependent on nonspecific targets, including anti-oxidative stress through a receptor-independent mechanism (La Rana et al. [@CR25]; Soliman et al. [@CR47]). Therefore, we suspect the positive effects of AM404 in our study might be through nonspecific targets. After carefully examined the results of this study, we suggest Akt could be the target of AM404. Therefore, we proposed a pathway for the current study (Supporting Information [S6](#MOESM1){ref-type="media"}). As shown in the figure, once the Akt is activated by AM404, the activated Akt (pS473Akt) could phosphorylate GSK3β (at S9 site, and become an inactive form), which could further reduce the features of AD, including Aβ, tau, inflammation, and cognitive impairment. Another study further indicated that the concentration of anandamide in rat plasma was increased in a time-dependent manner after systemic administration of AM404 (10 mg/kg, i.p.) (Giuffrida et al. [@CR16]). Therefore, chronic administration of AM404 at low dose attenuated cognitive deficit and related pathological features associated with Akt/GSK3β pathway, which might be increased by the concentration of anandamide in plasma or brain.

In this study, hyperglycemia increased BACE1 expression, Aβ deposition, tau protein phosphorylation, gliosis, and peripheral inflammation and decreased the levels of activated Akt and pS9-GSK3β (the inactive form of GSK3β) in 3×Tg-AD mice, whereas the AM404 treatment reversed these changes. Extracellular protofibrillar aggregates interfere directly with synaptic efficacy and play a crucial role on learning (Mohandas et al. [@CR32]). However, many evidences also suggest that intraneuronal Aβ accumulation impairs axonal transport and synaptic transmission thereby playing a role in the cognitive impairment associated with AD (Stokin et al. [@CR48]; Ripoli et al. [@CR43]). Intracellular Aβ deposition is the first clear neuropathological manifestation closely associated with synaptic dysfunction in the brains of 3×Tg-AD mice or other AD transgenic mouse models (Kuo et al. [@CR24]; Wirths et al. [@CR50]; Oddo et al. [@CR36]). The intraneuronal Aβ was firstly revealed within neurons at 3 weeks of age in 3xTg-AD mice (Oh et al. [@CR37]); however, extracellular aggregates were not observed until 12--14 months old (Oddo et al. [@CR36]; Yan et al. [@CR52]). Recent evidence showed that high glucose leads to the increased expression of genes related to Aβ production, such as BACE1 (Nagai et al. [@CR35]). The chronic systemic administration of AM404 at low dose reduced intracellular Aβ40 and Aβ42, which may be due to the reduction in BACE1 expression because no alteration was observed in the Aβ-metabolizing enzymes (IDE, NEP). Although we did not examine the enzymatic activity of these three enzymes including BACE1, IDE, and NEP, accumulating evidences have shown that the expression levels of production (BACE1) and degradation (IDE or NEP) enzymes of Aβ were consistently regulated with the enzymatic activities in the AD brains (Fukumoto et al. [@CR14]; Austin et al. [@CR3]; McAllister et al. [@CR30]; Marwarha et al. [@CR29]; Li et al. [@CR26]). Moreover, the reduction in the levels of pS473Akt and pS9-GSK3β in the brains of STZ-treated mice is consistent with the results of a recent study (Chowdhury et al. [@CR10]). In addition, GSK3β activity has been suggested to modulate BACE1 expression and subsequently regulate Aβ~42~ deposition (Zhou et al. [@CR56]). Furthermore, Aβ~25--35~ decreases Akt activation and increases the level of pS9-GSK3β (Naert et al. [@CR34]). Thus, AM404 may inhibit GSK3β activity and subsequently regulate Aβ deposition via an increase of pAkt expression levels to protect against hyperglycemic toxicity in 3×Tg-AD mice. A previous study suggested that the GSK3β phosphorylation sites corresponding to the formation of paired helical tau filaments include Ser202, Ser396, Thr181, and Thr231, according to the longest human tau isoform, which contains 441 residues (Hanger et al. [@CR19]). Recent evidence suggests that Aβ deposition and accumulation of phosphorylated tau proteins lead to inflammation in 3×Tg-AD mice (Ontiveros-Torres et al. [@CR38]). Furthermore, the anti-inflammatory property of AM404 observed here was consistent with a previous study (Roche et al. [@CR44]). Therefore, chronic systemic administration of AM404 at low dose used maybe reverse cognitive deficits via Akt/GSK3β pathway, not dependent on a direct GSK3β inhibitor, CB1, or TRP1 receptor in hyperglycemic 3×Tg-AD mice.

In summary, our results show that chronic systemic low dose of AM404 may serve as a potential therapy for AD.
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